LimmaTech sets up as de facto GSK vaccine R&D unit in wake of $190M buyout

Nick Paul Taylor

Biologics, a spillover from the $ 190 million (€169 million) takeover of GlycoVaxyn by GlaxoSmithKline, has opened its doors. The biotech is starting life with GlycoVaxyn's research operation and a 5-year agreement to pump novel bioconjugate antigen‐based vaccines into GSK's pipeline.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS